Low levels of 25-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 in patients with newly diagnosed type 1 diabetes

Paolo Pozzilli, Silvia Manfrini, Antonio Crinò, Antonio Picardi, Cesarea Leomanni, V. Cherubini, Luciana Valente, Manon Khazrai, Natalia Visalli, Elvira Fioriti, Giusy Coppolino, Chiara Guglielmi, Giuseppina Beretta Anguissola, Flavia Costanza, Anna Lisa Montemari, Gisella Cavallo, Riccardo Schiaffini, Angelo Lauria, Laura Cipolloni, Maria C. MatteoliPatrizia Patera, Stefania Corbi, Sabrina Spera, Concetta Suraci, Marco Cervoni, Giancarlo De Mattia, Maria R. Cassone Faldetta, Maria L. Manca Bitti, Carla Bizzarri, Marco Cappa, Dario Pitocco, Giovanni Ghirlanda

Research output: Contribution to journalArticle

Abstract

Background and aims: An epidemiological retrospective study and a recent prospective study from Finland have both concluded that vitamin D3 supplementation at birth protects individuals from type 1 diabetes later in life. Moreover, it is thought that vitamin D3 supplementation, in particular its activated form, 1,25-dihydroxyvitamin D3 [1,25-(OH)2D3], may act as an immunomodulator, facilitating the shift from a Th1 to a Th2 immune response. The aim of this surveillance study was to measure levels of both 25-hydroxyvitamin D3 (25OHD3) and 1,25- dihydroxyvitamin D3 in patients with newly diagnosed type 1 diabetes as compared to normal subjects. Methods: We measured plasma levels of 25-hydroxyvitamin D3 [25OHD3] and 1,25-dihydroxyvitamin D3 by radioimmunoassay in 88 consecutive patients with newly diagnosed type 1 diabetes (mean age 14.6 years; diagnosis within the last week), and in 57 healthy age and sex-matched subjects (mean age 16.5 years) born and residing in the Lazio region of continental Italy. Results: Mean levels of both 25OHD3 and 1,25-(OH)2D3 were significantly lower in patients compared to controls (p <0.01 and p <0.03, respectively). There was no correlation between 1,25-(OH) 2D3 plasma level and metabolic control status at disease diagnosis, age, gender, or most importantly, seasonality of disease diagnosis. This new observation endorses the findings of the Finnish study, even though Italy is a geographic area with more hours of sunlight than Finland. Conclusions: These findings suggest that vitamin D3 may be an important pathogenic factor in type 1 diabetes independent of geographical latitude, and that its supplementation should be considered not only at birth, but also at diagnosis of type 1 diabetes with the aim of favouring a Th2 immune response and protecting residual beta cells from further destruction.

Original languageEnglish
Pages (from-to)680-683
Number of pages4
JournalHormone and Metabolic Research
Volume37
Issue number11
DOIs
Publication statusPublished - Nov 2005

Fingerprint

Calcifediol
Calcitriol
Medical problems
Type 1 Diabetes Mellitus
Cholecalciferol
Finland
Italy
Parturition
Plasmas
Sunlight
Immunologic Factors
Radioimmunoassay
Epidemiologic Studies
Retrospective Studies
Observation
Prospective Studies

Keywords

  • Immune response
  • Type 1 diabetes
  • Vitamin D

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology

Cite this

Low levels of 25-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 in patients with newly diagnosed type 1 diabetes. / Pozzilli, Paolo; Manfrini, Silvia; Crinò, Antonio; Picardi, Antonio; Leomanni, Cesarea; Cherubini, V.; Valente, Luciana; Khazrai, Manon; Visalli, Natalia; Fioriti, Elvira; Coppolino, Giusy; Guglielmi, Chiara; Anguissola, Giuseppina Beretta; Costanza, Flavia; Montemari, Anna Lisa; Cavallo, Gisella; Schiaffini, Riccardo; Lauria, Angelo; Cipolloni, Laura; Matteoli, Maria C.; Patera, Patrizia; Corbi, Stefania; Spera, Sabrina; Suraci, Concetta; Cervoni, Marco; De Mattia, Giancarlo; Cassone Faldetta, Maria R.; Manca Bitti, Maria L.; Bizzarri, Carla; Cappa, Marco; Pitocco, Dario; Ghirlanda, Giovanni.

In: Hormone and Metabolic Research, Vol. 37, No. 11, 11.2005, p. 680-683.

Research output: Contribution to journalArticle

Pozzilli, P, Manfrini, S, Crinò, A, Picardi, A, Leomanni, C, Cherubini, V, Valente, L, Khazrai, M, Visalli, N, Fioriti, E, Coppolino, G, Guglielmi, C, Anguissola, GB, Costanza, F, Montemari, AL, Cavallo, G, Schiaffini, R, Lauria, A, Cipolloni, L, Matteoli, MC, Patera, P, Corbi, S, Spera, S, Suraci, C, Cervoni, M, De Mattia, G, Cassone Faldetta, MR, Manca Bitti, ML, Bizzarri, C, Cappa, M, Pitocco, D & Ghirlanda, G 2005, 'Low levels of 25-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 in patients with newly diagnosed type 1 diabetes', Hormone and Metabolic Research, vol. 37, no. 11, pp. 680-683. https://doi.org/10.1055/s-870578
Pozzilli, Paolo ; Manfrini, Silvia ; Crinò, Antonio ; Picardi, Antonio ; Leomanni, Cesarea ; Cherubini, V. ; Valente, Luciana ; Khazrai, Manon ; Visalli, Natalia ; Fioriti, Elvira ; Coppolino, Giusy ; Guglielmi, Chiara ; Anguissola, Giuseppina Beretta ; Costanza, Flavia ; Montemari, Anna Lisa ; Cavallo, Gisella ; Schiaffini, Riccardo ; Lauria, Angelo ; Cipolloni, Laura ; Matteoli, Maria C. ; Patera, Patrizia ; Corbi, Stefania ; Spera, Sabrina ; Suraci, Concetta ; Cervoni, Marco ; De Mattia, Giancarlo ; Cassone Faldetta, Maria R. ; Manca Bitti, Maria L. ; Bizzarri, Carla ; Cappa, Marco ; Pitocco, Dario ; Ghirlanda, Giovanni. / Low levels of 25-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 in patients with newly diagnosed type 1 diabetes. In: Hormone and Metabolic Research. 2005 ; Vol. 37, No. 11. pp. 680-683.
@article{1263ae6c15cb406d8f5de1fd023c10f6,
title = "Low levels of 25-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 in patients with newly diagnosed type 1 diabetes",
abstract = "Background and aims: An epidemiological retrospective study and a recent prospective study from Finland have both concluded that vitamin D3 supplementation at birth protects individuals from type 1 diabetes later in life. Moreover, it is thought that vitamin D3 supplementation, in particular its activated form, 1,25-dihydroxyvitamin D3 [1,25-(OH)2D3], may act as an immunomodulator, facilitating the shift from a Th1 to a Th2 immune response. The aim of this surveillance study was to measure levels of both 25-hydroxyvitamin D3 (25OHD3) and 1,25- dihydroxyvitamin D3 in patients with newly diagnosed type 1 diabetes as compared to normal subjects. Methods: We measured plasma levels of 25-hydroxyvitamin D3 [25OHD3] and 1,25-dihydroxyvitamin D3 by radioimmunoassay in 88 consecutive patients with newly diagnosed type 1 diabetes (mean age 14.6 years; diagnosis within the last week), and in 57 healthy age and sex-matched subjects (mean age 16.5 years) born and residing in the Lazio region of continental Italy. Results: Mean levels of both 25OHD3 and 1,25-(OH)2D3 were significantly lower in patients compared to controls (p <0.01 and p <0.03, respectively). There was no correlation between 1,25-(OH) 2D3 plasma level and metabolic control status at disease diagnosis, age, gender, or most importantly, seasonality of disease diagnosis. This new observation endorses the findings of the Finnish study, even though Italy is a geographic area with more hours of sunlight than Finland. Conclusions: These findings suggest that vitamin D3 may be an important pathogenic factor in type 1 diabetes independent of geographical latitude, and that its supplementation should be considered not only at birth, but also at diagnosis of type 1 diabetes with the aim of favouring a Th2 immune response and protecting residual beta cells from further destruction.",
keywords = "Immune response, Type 1 diabetes, Vitamin D",
author = "Paolo Pozzilli and Silvia Manfrini and Antonio Crin{\`o} and Antonio Picardi and Cesarea Leomanni and V. Cherubini and Luciana Valente and Manon Khazrai and Natalia Visalli and Elvira Fioriti and Giusy Coppolino and Chiara Guglielmi and Anguissola, {Giuseppina Beretta} and Flavia Costanza and Montemari, {Anna Lisa} and Gisella Cavallo and Riccardo Schiaffini and Angelo Lauria and Laura Cipolloni and Matteoli, {Maria C.} and Patrizia Patera and Stefania Corbi and Sabrina Spera and Concetta Suraci and Marco Cervoni and {De Mattia}, Giancarlo and {Cassone Faldetta}, {Maria R.} and {Manca Bitti}, {Maria L.} and Carla Bizzarri and Marco Cappa and Dario Pitocco and Giovanni Ghirlanda",
year = "2005",
month = "11",
doi = "10.1055/s-870578",
language = "English",
volume = "37",
pages = "680--683",
journal = "Hormone and Metabolic Research",
issn = "0018-5043",
publisher = "Georg Thieme Verlag",
number = "11",

}

TY - JOUR

T1 - Low levels of 25-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 in patients with newly diagnosed type 1 diabetes

AU - Pozzilli, Paolo

AU - Manfrini, Silvia

AU - Crinò, Antonio

AU - Picardi, Antonio

AU - Leomanni, Cesarea

AU - Cherubini, V.

AU - Valente, Luciana

AU - Khazrai, Manon

AU - Visalli, Natalia

AU - Fioriti, Elvira

AU - Coppolino, Giusy

AU - Guglielmi, Chiara

AU - Anguissola, Giuseppina Beretta

AU - Costanza, Flavia

AU - Montemari, Anna Lisa

AU - Cavallo, Gisella

AU - Schiaffini, Riccardo

AU - Lauria, Angelo

AU - Cipolloni, Laura

AU - Matteoli, Maria C.

AU - Patera, Patrizia

AU - Corbi, Stefania

AU - Spera, Sabrina

AU - Suraci, Concetta

AU - Cervoni, Marco

AU - De Mattia, Giancarlo

AU - Cassone Faldetta, Maria R.

AU - Manca Bitti, Maria L.

AU - Bizzarri, Carla

AU - Cappa, Marco

AU - Pitocco, Dario

AU - Ghirlanda, Giovanni

PY - 2005/11

Y1 - 2005/11

N2 - Background and aims: An epidemiological retrospective study and a recent prospective study from Finland have both concluded that vitamin D3 supplementation at birth protects individuals from type 1 diabetes later in life. Moreover, it is thought that vitamin D3 supplementation, in particular its activated form, 1,25-dihydroxyvitamin D3 [1,25-(OH)2D3], may act as an immunomodulator, facilitating the shift from a Th1 to a Th2 immune response. The aim of this surveillance study was to measure levels of both 25-hydroxyvitamin D3 (25OHD3) and 1,25- dihydroxyvitamin D3 in patients with newly diagnosed type 1 diabetes as compared to normal subjects. Methods: We measured plasma levels of 25-hydroxyvitamin D3 [25OHD3] and 1,25-dihydroxyvitamin D3 by radioimmunoassay in 88 consecutive patients with newly diagnosed type 1 diabetes (mean age 14.6 years; diagnosis within the last week), and in 57 healthy age and sex-matched subjects (mean age 16.5 years) born and residing in the Lazio region of continental Italy. Results: Mean levels of both 25OHD3 and 1,25-(OH)2D3 were significantly lower in patients compared to controls (p <0.01 and p <0.03, respectively). There was no correlation between 1,25-(OH) 2D3 plasma level and metabolic control status at disease diagnosis, age, gender, or most importantly, seasonality of disease diagnosis. This new observation endorses the findings of the Finnish study, even though Italy is a geographic area with more hours of sunlight than Finland. Conclusions: These findings suggest that vitamin D3 may be an important pathogenic factor in type 1 diabetes independent of geographical latitude, and that its supplementation should be considered not only at birth, but also at diagnosis of type 1 diabetes with the aim of favouring a Th2 immune response and protecting residual beta cells from further destruction.

AB - Background and aims: An epidemiological retrospective study and a recent prospective study from Finland have both concluded that vitamin D3 supplementation at birth protects individuals from type 1 diabetes later in life. Moreover, it is thought that vitamin D3 supplementation, in particular its activated form, 1,25-dihydroxyvitamin D3 [1,25-(OH)2D3], may act as an immunomodulator, facilitating the shift from a Th1 to a Th2 immune response. The aim of this surveillance study was to measure levels of both 25-hydroxyvitamin D3 (25OHD3) and 1,25- dihydroxyvitamin D3 in patients with newly diagnosed type 1 diabetes as compared to normal subjects. Methods: We measured plasma levels of 25-hydroxyvitamin D3 [25OHD3] and 1,25-dihydroxyvitamin D3 by radioimmunoassay in 88 consecutive patients with newly diagnosed type 1 diabetes (mean age 14.6 years; diagnosis within the last week), and in 57 healthy age and sex-matched subjects (mean age 16.5 years) born and residing in the Lazio region of continental Italy. Results: Mean levels of both 25OHD3 and 1,25-(OH)2D3 were significantly lower in patients compared to controls (p <0.01 and p <0.03, respectively). There was no correlation between 1,25-(OH) 2D3 plasma level and metabolic control status at disease diagnosis, age, gender, or most importantly, seasonality of disease diagnosis. This new observation endorses the findings of the Finnish study, even though Italy is a geographic area with more hours of sunlight than Finland. Conclusions: These findings suggest that vitamin D3 may be an important pathogenic factor in type 1 diabetes independent of geographical latitude, and that its supplementation should be considered not only at birth, but also at diagnosis of type 1 diabetes with the aim of favouring a Th2 immune response and protecting residual beta cells from further destruction.

KW - Immune response

KW - Type 1 diabetes

KW - Vitamin D

UR - http://www.scopus.com/inward/record.url?scp=29144446163&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=29144446163&partnerID=8YFLogxK

U2 - 10.1055/s-870578

DO - 10.1055/s-870578

M3 - Article

C2 - 16308836

AN - SCOPUS:29144446163

VL - 37

SP - 680

EP - 683

JO - Hormone and Metabolic Research

JF - Hormone and Metabolic Research

SN - 0018-5043

IS - 11

ER -